Become a logicalchat Member

Latest Post

How New Financial Technologies (FinTech) are Changing the Way Canadians Bank and Invest

The Canadian financial landscape is undergoing a significant transformation driven by innovative FinTech (financial technology) companies. These companies are leveraging technology to disrupt traditional...

Your story starts here. Sign up and let's connect in ways that truly matter!

HomeStocks in FocusToday's Top Performers: Geron, Adobe and Ulta Beauty more Shake...

Today’s Top Performers: Geron, Adobe and Ulta Beauty more Shake Up Markets Today.

Today’s Top Performers

After digesting the new inflation data, which was hotter than predicted, stock futures were mostly steady early Friday.

Top stock gainers


Geron (NASDAQ:GERN):- After FDA advisors voted 12–2 in support of Geron (NASDAQ:GERN)’s imetelstat blood cancer treatment for transfusion-dependent anemia in MDS patients, shares rose 94%. FDA cancer medication specialists considered imetelstat a late-line alternative with benefits outweighing dangers. Gérardon’s flagship asset, imetelstat, is under FDA assessment for lower-risk MDS. A decision is due by June 16. FDA follows advisory committee recommendations, although they are non-binding.


Madrigal Pharmaceuticals’ (NASDAQ:MDGL):- After the FDA authorized resmetirom, Madrigal Pharmaceuticals’ (NASDAQ:MDGL) flagship asset, as the first U.S. treatment for nonalcoholic steatohepatitis (NASH), shares rose 28%. Since there were no FDA-approved medicines for NASH, a deadly liver disease, REZDIFFRA represents a medical breakthrough. This approval is a tremendous step forward for NASH, now called metabolic dysfunction-associated steatohepatitis (MASH), which has no viable treatments. Resmetirom can be taken alongside diet and exercise for persons with NASH and moderate-to-advanced liver fibrosis, according to the FDA.

Top stock losses

Adobe (NASDAQ:ADBE) fell 11% after exceeding FQ1 earnings forecasts, due to a disappointing FQ2 outlook. Adobe expects adjusted EPS of $4.35–$4.40 in FQ2, compared to a consensus of $4.38. Revenue expectations are $5.25B to $5.3B, below consensus of $5.31B. Digital Experience revenue is estimated to be $1.31B to $1.33B, while Digital Media revenue is $3.87B to $3.9B. Net new annual recurring revenue for the division is expected to be $440M. Adobe’s directors also announced a $25B share purchase.


Ulta Beauty (NASDAQ:ULTA):- Despite better-than-expected Q4 results, Ulta Beauty (NASDAQ:ULTA) shares fell 7% owing to conservative 2024 profit outlook and lackluster comparative sales. Given the volatile macro climate, CEO Dave Kimball was optimistic about the beauty category’s resilience in 2024. Ulta (ULTA) forecasts 2024 sales of $11.7B to $11.8B and profits per share of $26.20 to $27, below the average expectation of $27.03. Comparable sales are expected to rise 4%–5%, down from 5.7% in 2023. From 15% in 2023, the operating margin should drop to 14% to 14.3%. Ulta (ULTA) also announced a 2025 joint venture with Axo to build and run Ulta Beauty in Mexico.

Must read book about investing – check here Today’s Top Performers Today’s Top Performers Today’s Top Performers Today’s Top Performers

After reporting 8% Y/Y subscription revenue growth in 4Q24, DocuSign (NASDAQ:DOCU) shares rose 10%. Electronic signature business predicts 1Q25 revenue of $704M to $708M, above analysts’ $699.1M forecast. DocuSign expects sales of $2.91B to $2.92B this year, with consensus of $2.91B. Customer adoption of Contract Lifecycle Management and eSignature in StateRAMP-authorized environments was also emphasized by the organization.

MongoDB (NASDAQ:MDB) shares fell 8% after exceeding Q4 profit and sales forecasts owing to its dovish FY2025 outlook. MongoDB expects revenues of $436M to $440M in Q1, below the average expectation of $449.08M. Below the estimate of $0.61, non-GAAP EPS is expected to be $0.34–$0.39. The business estimates FY2024 sales between $1.9B and $1.93B, below the average of $2.03B. Unlike the consensus of $3.22, non-GAAP EPS is expected to be $2.27 to $2.49.

Marvell Technology (NASDAQ:MRVL) shares fell over 7% after solid Q4 earnings due to a dismal Q1 guidance. The business predicts Q1 sales of $1.15B, plus or less 5%, behind analysts’ $1.36B. Marvell predicts adjusted gross margins of 62% to 63% and adjusted earnings of $0.18 to $0.28 per share, significantly below the average forecast of $0.40. Marvell announced $3B in stock buybacks.

Despite a 5.7% Y/Y rise, Costco Wholesale’s NASDAQ:COST shares plummeted roughly 4% as its FQ2 earnings reports fell short of the top-line estimate. Comparable sales increased by 5.6% during the quarter, above the 5.1% estimate.

MongoDB (NASDAQ:MDB) shares fell 8% after exceeding Q4 profit and sales forecasts owing to its dovish FY2025 outlook. MongoDB expects revenues of $436M to $440M in Q1, below the average expectation of $449.08M. Below the estimate of $0.61, non-GAAP EPS is expected to be $0.34–$0.39. The business estimates FY2024 sales between $1.9B and $1.93B, below the average of $2.03B. Unlike the consensus of $3.22, non-GAAP EPS is expected to be $2.27 to $2.49.

Marvell Technology (NASDAQ:MRVL) shares fell over 7% after solid Q4 earnings due to a dismal Q1 guidance. The business predicts Q1 sales of $1.15B, plus or less 5%, behind analysts’ $1.36B. Marvell predicts adjusted gross margins of 62% to 63% and adjusted earnings of $0.18 to $0.28 per share, significantly below the average forecast of $0.40. Marvell announced $3B in stock buybacks.

Despite a 5.7% Y/Y rise, Costco Wholesale’s NASDAQ:COST shares plummeted roughly 4% as its FQ2 earnings reports fell short of the top-line estimate. Comparable sales increased by 5.6% during the quarter, above the 5.1% estimate.

Related Post